A new TNM classification for breast cancer to meet the demands of the present and the challenges of the future

Women's Health

Volumn 7, Issue 1, 2011, Pages 41-49

  Zurrida, Stefano ^a,b   Veronesi, Umberto ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

biological factors; breast cancer; cancer stem cells; ductal intraepithelial neoplasia; lobular intraepithelial neoplasia; TNM

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESEARCH; CANCER STAGING; CANCER STEM CELL; CARCINOMATOSIS; CELL RENEWAL; CLINICAL PRACTICE; COPY NUMBER VARIATION; DISTANT METASTASIS; DOCTOR PATIENT RELATION; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; NOMENCLATURE; PROGNOSIS; PROGRAM DEVELOPMENT; TREATMENT PLANNING; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA IN SITU; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS;

EID: 78650631782     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.82     Document Type: Article

References (31)

1. Denoix PF, Schwartz D: General rules for classification of cancers and presentation of the therapeutic results. Mem. Acad. Chir. (Paris) 85(15-16), 415-424 (1959).
2. Odicino F, Pecorelli S, Zigliani L, Creasman WT: History of the FIGO cancer staging system: Int. J. Gynaecol Obstet. 101(2), 205-210 (2008).
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). AJCC cancer Staging Manual (Seventh Ed). Springer, NY, USA (2010).
4. Sobin LH, Gospodarowicz MK, Wittekind C (Eds). TNM Classification of Malignant Tumours (Seventh Ed) Wiley-Blackwell, NJ, USA (2009).
5. Veronesi U, Viale G, Rotmensz N, Goldhirsch A: Rethinking TNM: Breast cancer TNM classification for treatment decision-making and research: the breast. 15(1), 3-8 (2006).
6. Veronesi U, Zurrida S, Viale G, Galimberti V, Arnone P, Nolè F: Rethinking TNM: a breast ancer classification to guide to treatment and facilitate research. Breast J. 3, 291-295 (2009).
7. Veronesi U, Zurrida S, Goldhirsch A, Rotmensz N, Viale G: Breast cancer classification: time for a change. J. Clin. Oncol. 27(15), 2427-2428 (2009).
8. Derogatis LR, Morrow GR, Fetting J et al.: The prevalence of psychiatric disorders among cancer patients. JAMA 249 (6), 751-757 (1983).
9. Leydon GM, Boulton M, Moynihan C et al.: Cancer Patients information needs and information seeking behaviour: in depth interview study. BMJ. 320 (7239), 909-913 (2000).
10. Costelloe M, Nelson L: The needs of recently diagnosed cancer patients. Nurs. Stand. 19(13), 42-44 (2004).
11. Tavassoli FA: Ductal carcinoma N: introduction of the concept of ductal intraepithelial neoplasia. Mod. Pathol. 11, 140-154 (1998).
12. Veronesi U, Paganelli G, Viale G et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349, 546-553 (2003).
13. Veronesi U, Zurrida S, Mazzarol G, Viale G: Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. World J. Surg. 25(6), 806-808 (2001).
14. Galimberti V: International breast cancer study group trial of sentinel node biopsy. J. Clin. Oncol. 24(1), 210-211 (2006).
15. Fernando HC: Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases. Ann. Thor. Surg. 85, S780-S784 (2008).
16. Ranjan T, Abrey LE: Current management of metastatic brain disease. Neurotherapeutics 6(3), 598-603 (2009).
17. Kennedy JE: High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 5(4), 321-327 (2005).
18. Chiappa A, Makuuchi M, Lygidakis NJ et al.: The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit. Rev. Oncol. Hematol. 72(1), 65-75 (2009).
19. Paganelli G, Chinol M: Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur. J. Nucl. Med. Mol. Imaging 30(5), 773-776 (2003).
20. Silvestrini R, Daidone MG:, Mastore M et al.: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J. Clin. Oncol. 6, 1150-1155 (1993).
21. Goldhirod WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann. Oncol.18(7), 1133-1144 (2007).
22. Curigliano G, Viale G, Bagnardi PV et al.: Clinical Relevance of HER2 Overexpression/amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol. 27, 5693-5699 (2009).
23. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol 17, 1983-1987 (1999).
24. Persons DL, Tubbs RR, Cooley LD et al.: HER-2 fluorescence N hybridization: Results from the survey program of the College of American Pathologists. Arch. Pathol. Lab. Med. 130, 325-331 (2006).
25. Gong Y, Yan K, Lin F et al.: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 8(3), 203-211 (2007).
26. Dal Lago L, Durbecq V, Desmedt C et al.: Correction for chromosome 17 is critical for determination of true Her-2/neu gene amplification status in breast cancer. Mol. Cancer Ther. 5, 2572-2579 (2006).
27. Perou CM, Srlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
28. Loi S: Molecular analysis of hormone receptor positive (luminal) breast cancers - what have we learnt? Eur. J. Cancer 44, 2813-2818 (2008).
29. Weigelt B, Mackay A, Ahern R et al.: Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 4, 339-349 (2010).
30. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N. Engl. J. Med. 360, 790-800 (2009).
31. Srlie T, Perou CM, Tibshirani R et al.: Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).